August 23, 2016 03:43 PM EDT

Clovis soars as its PARP drug rucaparib lines up for FDA review with positive data

John Carroll

Editor & Founder

Clovis Oncology stock $CLVS shot up 30% Tuesday afternoon after the biotech laid out competitive pivotal data for its PARP inhibitor rucaparib, which has …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Clovis soars as its PARP drug rucaparib lines up for FDA review with positive data

John Carroll

Editor & Founder

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Bristol Myers sues the federal government over 340B, following other drugmakers

Clo­vis soars as its PARP drug ru­ca­parib lines up for FDA re­view with pos­i­tive da­ta

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Clovis soars as its PARP drug rucaparib lines up for FDA review with positive data

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Bristol Myers sues the federal government over 340B, following other drugmakers